Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „sorafenib“
Suchtreffer
Begriffe & Kennungen
Nexavar · 4.5 · 7 o Co-administration of paclitaxel (225 mg/m2, once every 3 weeks) and carboplatin (AUC=6) with sorafenib (40
Eintrag öffnenNexavar · 4.5 · Administration of rifampicin for 5 days before administration of a single dose of sorafenib resulted in an ave
Eintrag öffnenNexavar · 4.5 · CYP1A2 and CYP3A4 activities were not altered after treatment of cultured human hepatocytes with sorafenib, in
Eintrag öffnenNexavar · 4.5 · Co-administration of capecitabine (750-1050 mg/m2 twice daily, Days 1-14 every 21 days) and sorafenib (200 or
Eintrag öffnenNexavar · 4.5 · Concomitant administration of sorafenib and midazolam, dextromethorphan or omeprazole, which are substrates fo
Eintrag öffnenNexavar · 4.5 · Concomitant treatment with sorafenib resulted in a 21 % increase in the AUC of doxorubicin. When administered
Eintrag öffnenNexavar · 4.5 · Docetaxel (75 or 100 mg/m2 administered once every 21 days) when co-administered with sorafenib (200 mg twice
Eintrag öffnenNexavar · 4.5 · In clinical studies sorafenib has been administered with a variety of other anti-neoplastic agents at their co
Eintrag öffnenNexavar · 4.5 · In vitro, sorafenib has been shown to inhibit the transport protein p-glycoprotein (P-gp). Increased plasma co
Eintrag öffnenNexavar · 4.5 · In vitro, sorafenib inhibited glucuronidation via UGT1A1 and UGT1A9. The clinical relevance of this finding is
Eintrag öffnenNexavar · 4.5 · Sorafenib inhibited CYP2B6, CYP2C8 and CYP2C9 in vitro with similar potency. However, in clinical pharmacokine
Eintrag öffnenNexavar · 4.5 · o Administration of paclitaxel (225 mg/m2) and carboplatin (AUC = 6) with sorafenib (≤ 400 mg twice daily), ad
Eintrag öffnenNexavar · 4.8 · CTCAE Grade 3 or 4 laboratory abnormalities occurring in ≥ 5 % of sorafenib treated patients included lymphope
Eintrag öffnenNexavar · 4.8 · Hypocalcaemia was reported in 12% and 26.5% of sorafenib treated patients compared to 7.5% and 14.8% of placeb
Eintrag öffnenNexavar · 4.8 · Hypocalcaemia was reported in 35.7% of sorafenib treated patients compared to 11.0% of placebo patients. Most
Eintrag öffnenNexavar · 4.8 · Hypophosphataemia was a very common laboratory finding, observed in 45 % and 35 % of sorafenib treated patient
Eintrag öffnenNexavar · 4.8 · In studies 1 and 3 decreased potassium was observed in 5.4% and 9.5% of sorafenib-treated patients compared to
Eintrag öffnenNexavar · 4.8 · Laboratory parameter, Sorafenib N=207 Placebo N=209 (in % of samples All Grade Grade All Grade Grade investiga
Eintrag öffnenRetsevmo · 4.5 · 9 amodiaquine, cerivastatin, enzalutamide, paclitaxel, repaglinide, torasemide, sorafenib, rosiglitazone, bupr
Eintrag öffnenSorafenib
Eintrag öffnen